Impact of Reproductive Factors and Hormone Replacement Therapy on Disease Severity in Women with Pulmonary Arterial Hypertension: Insights from the United States Pulmonary Hypertension Scientific Registry

BackgroundPulmonary arterial hypertension (PAH) is a devastating disease that affects women more often than men; recent U.S. cohorts demonstrate a female:male ratio of 3 to 4:1. Paradoxically, males have worse survival. The differential effects of sex hormones, particularly estrogen, on the pulmonary vasculature and right ventricle likely account for some of these differences. The role of female-specific risk factors, such as reproductive exposures, are poorly understood in the pathophysiology of PAH. Research QuestionTo investigate the role of reproductive factors and exogenous estrogen exposures in PAH onset and severity in women enrolled in the United States Pulmonary Hypertension Scientific Registry (USPHSR). Study Design and MethodsUsing questionnaires from 390 women with PAH, enrolled in both the PAH Biobank and USPHSR, we conducted linear regression analyses to assess the association between patient reported reproductive variables and PAH disease severity variables, as well as REVEAL Lite 2.0 scores. We adjusted for potential confounders including age, race, BMI, and PAH sub-group (idiopathic, heritable, associated). ResultsYounger menopause age (< 40 years) associates with a lower cardiac index (CI) at diagnosis, even when controlling for use of hormone replacement therapy (HRT). There was a trend toward lower CI in women with menopause age of 41-50 years. Women who had ever used HRT were diagnosed with PAH an average of 13.4 years later and "ever use" of HRT associates with higher pulmonary vascular resistance and lower CI at diagnosis. InterpretationPremature menopause (age < 40 years) and ever use of HRT associate with worse hemodynamics, including lower CI, at diagnosis in women with PAH. Further investigations into reproductive history and estrogen exposures may offer an opportunity for more comprehensive risk factor screening and modification by physicians treating patients with PAH.